U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Serous cystadenocarcinoma

MedGen UID:
60212
•Concept ID:
C0206701
•
Neoplastic Process
Synonyms: Cystadenocarcinoma, Serous; Cystadenocarcinomas, Serous; Serous Cystadenocarcinoma; Serous Cystadenocarcinomas
SNOMED CT: Serous cystadenocarcinoma (90725004); Serous adenocarcinoma (90725004); Serous carcinoma (90725004); Papillary serous cystadenocarcinoma (90725004); Papillary serous adenocarcinoma (90725004); Serous surface papillary carcinoma (90725004)
 
Monarch Initiative: MONDO:0024621

Definition

An adenocarcinoma that is characterized by the presence of papillary patterns and cellular budding. Psammoma bodies may be present. Representative examples include cervical serous adenocarcinoma, endometrial serous adenocarcinoma, ovarian serous adenocarcinoma, and primary peritoneal serous adenocarcinoma. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVSerous cystadenocarcinoma

Professional guidelines

PubMed

APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S, Li Y, Xu J, Shen L
Neurol Res 2024 Mar;46(3):227-242. Epub 2024 Jan 22 doi: 10.1080/01616412.2023.2287340. PMID: 38007705
A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma.
Xiong DD, Qin Y, Xu WQ, He RQ, Wu HY, Wei DM, Zeng JJ, Dang YW, Chen G
Clin Drug Investig 2018 Oct;38(10):909-925. doi: 10.1007/s40261-018-0683-8. PMID: 30097905
Management of serous cystic neoplasms of the pancreas.
Antonini F, Fuccio L, Fabbri C, Macarri G, Palazzo L
Expert Rev Gastroenterol Hepatol 2015 Jan;9(1):115-25. Epub 2014 Jul 1 doi: 10.1586/17474124.2014.934675. PMID: 24981593

Recent clinical studies

Etiology

Histopathologic image-based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer.
Ahn B, Moon D, Kim HS, Lee C, Cho NH, Choi HK, Kim D, Lee JY, Nam EJ, Won D, An HJ, Kwon SY, Shin SJ, Jung HR, Kwon D, Park H, Kim M, Cha YJ, Park H, Lee Y, Noh S, Lee YM, Choi SE, Kim JM, Sung SH, Park E
Nat Commun 2024 May 18;15(1):4253. doi: 10.1038/s41467-024-48667-6. PMID: 38762636Free PMC Article
Low-grade serous ovarian cancer: State of the science.
Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O'Malley DM, Lecuru F, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Fernández ML, Ray-Coquard I, Gershenson DM
Gynecol Oncol 2020 Mar;156(3):715-725. Epub 2020 Jan 20 doi: 10.1016/j.ygyno.2019.12.033. PMID: 31969252
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.
Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C
Int J Mol Sci 2019 Feb 22;20(4) doi: 10.3390/ijms20040952. PMID: 30813239Free PMC Article
Management of serous cystic neoplasms of the pancreas.
Antonini F, Fuccio L, Fabbri C, Macarri G, Palazzo L
Expert Rev Gastroenterol Hepatol 2015 Jan;9(1):115-25. Epub 2014 Jul 1 doi: 10.1586/17474124.2014.934675. PMID: 24981593
Critical molecular abnormalities in high-grade serous carcinoma of the ovary.
Köbel M, Huntsman D, Gilks CB
Expert Rev Mol Med 2008 Aug 1;10:e22. doi: 10.1017/S146239940800077X. PMID: 18671886

Diagnosis

Histopathologic image-based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer.
Ahn B, Moon D, Kim HS, Lee C, Cho NH, Choi HK, Kim D, Lee JY, Nam EJ, Won D, An HJ, Kwon SY, Shin SJ, Jung HR, Kwon D, Park H, Kim M, Cha YJ, Park H, Lee Y, Noh S, Lee YM, Choi SE, Kim JM, Sung SH, Park E
Nat Commun 2024 May 18;15(1):4253. doi: 10.1038/s41467-024-48667-6. PMID: 38762636Free PMC Article
HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting.
Buza N
Int J Gynecol Pathol 2021 Jan;40(1):17-23. doi: 10.1097/PGP.0000000000000711. PMID: 33290351
Low-grade Serous Tumors: Are We Making Progress?
Pauly N, Ehmann S, Ricciardi E, Ataseven B, Bommert M, Heitz F, Prader S, Schneider S, du Bois A, Harter P, Baert T
Curr Oncol Rep 2020 Jan 27;22(1):8. doi: 10.1007/s11912-020-0872-5. PMID: 31989304
Acquired chemotherapy resistance in ovarian cancer.
Christie EL, Bowtell DDL
Ann Oncol 2017 Nov 1;28(suppl_8):viii13-viii15. doi: 10.1093/annonc/mdx446. PMID: 29232469
Recently identified drug resistance biomarkers in ovarian cancer.
Davidson B
Expert Rev Mol Diagn 2016;16(5):569-78. Epub 2016 Mar 12 doi: 10.1586/14737159.2016.1156532. PMID: 26895188

Therapy

Low-grade serous ovarian cancer: expert consensus report on the state of the science.
Grisham RN, Slomovitz BM, Andrews N, Banerjee S, Brown J, Carey MS, Chui H, Coleman RL, Fader AN, Gaillard S, Gourley C, Sood AK, Monk BJ, Moore KN, Ray-Coquard I, Shih IM, Westin SN, Wong KK, Gershenson DM
Int J Gynecol Cancer 2023 Sep 4;33(9):1331-1344. doi: 10.1136/ijgc-2023-004610. PMID: 37591609Free PMC Article
Uterine serous carcinoma.
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Nout RA, Lorusso D, Vaughan MM, Bini M, Takano M, Provencher D, Indini A, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Candido Dos Reis FJ, Lopez S, Mariani A, Leitao MM Jr, Raspagliesi F, Panici PB, Di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ
Gynecol Oncol 2021 Jul;162(1):226-234. Epub 2021 Apr 30 doi: 10.1016/j.ygyno.2021.04.029. PMID: 33934848Free PMC Article
Low-grade serous ovarian cancer: State of the science.
Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O'Malley DM, Lecuru F, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Fernández ML, Ray-Coquard I, Gershenson DM
Gynecol Oncol 2020 Mar;156(3):715-725. Epub 2020 Jan 20 doi: 10.1016/j.ygyno.2019.12.033. PMID: 31969252
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD
J Clin Oncol 2018 Jul 10;36(20):2044-2051. Epub 2018 Mar 27 doi: 10.1200/JCO.2017.76.5966. PMID: 29584549
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
Moschetta M, George A, Kaye SB, Banerjee S
Ann Oncol 2016 Aug;27(8):1449-55. Epub 2016 Mar 31 doi: 10.1093/annonc/mdw142. PMID: 27037296

Prognosis

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley WH, Holmes E, Lowe ES, DiSilvestro P
Lancet Oncol 2021 Dec;22(12):1721-1731. Epub 2021 Oct 26 doi: 10.1016/S1470-2045(21)00531-3. PMID: 34715071
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger PB, Rudaitis V, Katchar K, Wu H, Keefe S, Ruman J, Ledermann JA
Ann Oncol 2019 Jul 1;30(7):1080-1087. doi: 10.1093/annonc/mdz135. PMID: 31046082
Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.
Peres LC, Cushing-Haugen KL, Köbel M, Harris HR, Berchuck A, Rossing MA, Schildkraut JM, Doherty JA
J Natl Cancer Inst 2019 Jan 1;111(1):60-68. doi: 10.1093/jnci/djy071. PMID: 29718305Free PMC Article
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR
Nat Rev Cancer 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. PMID: 26493647Free PMC Article
Clinical management of uterine papillary serous carcinoma.
Roelofsen T, van Ham MA, de Hullu JA, Massuger LF
Expert Rev Anticancer Ther 2011 Jan;11(1):71-81. doi: 10.1586/era.10.199. PMID: 21166512

Clinical prediction guides

Histopathologic image-based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer.
Ahn B, Moon D, Kim HS, Lee C, Cho NH, Choi HK, Kim D, Lee JY, Nam EJ, Won D, An HJ, Kwon SY, Shin SJ, Jung HR, Kwon D, Park H, Kim M, Cha YJ, Park H, Lee Y, Noh S, Lee YM, Choi SE, Kim JM, Sung SH, Park E
Nat Commun 2024 May 18;15(1):4253. doi: 10.1038/s41467-024-48667-6. PMID: 38762636Free PMC Article
Increased osteopontin expression in endometrial carcinoma is associated with better survival outcome.
Al Maghrabi H, Gomaa W, Al-Maghrabi J
Ginekol Pol 2020;91(2):73-78. doi: 10.5603/GP.2020.0020. PMID: 32141052
p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
Singh N, Piskorz AM, Bosse T, Jimenez-Linan M, Rous B, Brenton JD, Gilks CB, Köbel M
J Pathol 2020 Mar;250(3):336-345. Epub 2020 Jan 29 doi: 10.1002/path.5375. PMID: 31829441
Ovarian High-Grade Serous Carcinoma: Assessing Pathology for Site of Origin, Staging and Post-neoadjuvant Chemotherapy Changes.
Casey L, Singh N
Surg Pathol Clin 2019 Jun;12(2):515-528. doi: 10.1016/j.path.2019.01.007. PMID: 31097113
Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D, Dowe T, Santos JL, Cook LS, Tinker AV, Le ND, Gilks CB, Singh N
J Clin Oncol 2015 Aug 1;33(22):2457-63. Epub 2015 Jun 29 doi: 10.1200/JCO.2014.60.5212. PMID: 26124480

Recent systematic reviews

Micropapillary pattern in serous borderline ovarian tumor and the risk of extraovarian localization of low-grade serous carcinoma ('invasive implants'): A systematic review and meta-analysis.
Scaglione G, Travaglino A, Raffone A, Santoro A, Arciuolo D, Fulgione C, D'Alessandris N, Pannone G, Urtueta BP, Narducci N, Addante F, Casarin J, Ronchi S, Di Lauro E, La Rosa S, Maccio L, Inzani F, Zannoni GF
Pathol Res Pract 2024 Dec;264:155714. Epub 2024 Nov 6 doi: 10.1016/j.prp.2024.155714. PMID: 39520971
Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas.
Matsuo K, Matsuzaki S, Maeda M, Rau AR, Yoshihara K, Tamura R, Shimada M, Machida H, Mikami M, Klar M, Roman LD, Wright JD, Sood AK, Gershenson DM
JAMA Netw Open 2023 Jun 1;6(6):e2318602. doi: 10.1001/jamanetworkopen.2023.18602. PMID: 37326992Free PMC Article
Outcome and Management of Serous Tubal Intraepithelial Carcinoma Following Opportunistic Salpingectomy: Systematic Review and Meta-Analysis.
Ruel-Laliberté J, Kasasni SM, Oprea D, Viau M
J Obstet Gynaecol Can 2022 Nov;44(11):1174-1180. Epub 2022 Sep 12 doi: 10.1016/j.jogc.2022.08.018. PMID: 36099965
Incidence of omental metastasis in uterine serous carcinoma: a systematic review and meta-analysis.
Xu H, Cui SS, Ran L, Liu Y, Hu C, Xu Y, Tian Y
J Gynecol Obstet Hum Reprod 2022 Jun;51(6):102395. Epub 2022 Apr 28 doi: 10.1016/j.jogoh.2022.102395. PMID: 35489712
Recommendations for diagnosing STIC: a systematic review and meta-analysis.
Bogaerts JMA, Steenbeek MP, van Bommel MHD, Bulten J, van der Laak JAWM, de Hullu JA, Simons M
Virchows Arch 2022 Apr;480(4):725-737. Epub 2021 Dec 1 doi: 10.1007/s00428-021-03244-w. PMID: 34850262Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • MeSH
      Related Medical Subject Headings
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...